28 Nov 2008

Biotech company may de-list

7:27 am on 28 November 2008

Botry Zen made a loss of $1.2 million in the September half year and says it may de-list from the stock exchange.

The biotech company says production problems, and asset and stock write-downs contributed to the loss.

Chairman Stephen Higgs says Botry Zen needs to raise more capital in coming months.

Shares in the company are trading at $1.50 apiece.